RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2020 to Q2 2025

Type / Class
Equity / Common Stock
Symbol
DNA on NYSE
Shares outstanding
382,523,969
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAILLIE GIFFORD & CO 6.5% -30% $5,718,733 -$125,747 24,864,058 -1.5% BAILLIE GIFFORD & CO 31 Dec 2024

Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (DNA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q2 0 $0 -$203,000 0
2025 Q1 606,634 $203,000 +$203,000 $0.33 1
2024 Q4 0 $0 -$128,803 0
2024 Q3 18,945 $125,460 -$301,879,516 $0.33 6
2024 Q2 932,642,413 $311,412,586 -$140,817,814 $0.33 303
2024 Q1 1,295,131,199 $1,502,666,435 +$34,953,568 $1.16 328
2023 Q4 1,264,067,636 $2,135,655,316 +$35,010,634 $1.69 328
2023 Q3 1,240,312,565 $2,245,097,773 +$49,927,444 $1.81 342
2023 Q2 1,209,022,771 $2,248,308,746 +$138,253,220 $1.86 305
2023 Q1 1,138,832,894 $1,513,754,471 +$188,812,259 $1.33 308
2022 Q4 994,200,228 $1,680,167,004 +$184,329,564 $1.69 311
2022 Q3 878,617,048 $2,743,130,023 +$305,100,080 $3.12 257
2022 Q2 787,669,463 $1,933,096,110 +$286,080,459 $2.38 245
2022 Q1 666,585,740 $2,678,164,885 -$1,015,524,006 $4.03 180
2021 Q4 896,807,871 $7,383,978,168 +$844,855,283 $8.31 158
2021 Q3 792,062,901 $9,177,440,180 +$9,177,091,180 $11.59 122
2020 Q2 15,000 $36,000 $2.40 1